Business Daily from THE HINDU group of publications
Monday, September 8, 2008
ePaper | Mobile/PDA Version | Audio

News
Features
Stocks
Cross Currency
Shipping
Archives
Google

Subscription

Group Sites

Update at 1330 hrs (IST)


Corporate
Aurobindo gets FDA nod for AIDS drug

MUMBAI: Drug maker Aurobindo Pharma on Monday said it has received tentative approval from US Food and Drug Administration (USFDA) to manufacture and market Abacavir Sulfate and Lamivudine tablets, used in the treatment of HIV (human immunodeficiency vir us).

The tablets are the generic equivalent of Epizcom tablets of Smithkline Beecham corporation and falls under the anti-retroviral segment, the company said in a filling to the Bombay Stock Exchange.

Aurobindo Pharma would manufacture and market Abacavir Sulfate/ Lamivudine tablets in the strengths of 600 mg and 300 mg, the filing said.

The products have been reviewed under the President's emergency plan for AIDS relief. This is Aurobindo 76th abbreviated new drug application approval from US FDA.

Shares of the company were trading at Rs 320, up 1.25 per cent in afternoon trade on the BSE. - PTI

Prev: Rupee recovers sharply
Next: Essential drugs become scarce in India, Africa


Business Line | NUS Index |



Related Topics
Alliances & Joint Ventures
Announcements
Auditing
Awards & Honours
Bonus Announcements
Company Law
Corporate Bonds
Corporate Disputes
Corporate Governance
Courts/Legal Issues
Diversification
Environment
Human Resources
Interview
IPOs
IPR
Management
Mergers & Acquisitions
New Projects
Open Offers
Outlook
Outsourcing
Overseas Borrowings
Overseas Investments
People
Performance
Preferential Allotments
Private Placement
Regulatory Bodies & Rulings
Research & Development
Restructuring
Rights Issue
Sick Units
Society & Development
Standards & Benchmarks
Taxation
Trade & Labour Unions



The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | Business Line | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |

Copyright © 2008, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line